Placebo to NVA237

DRUG4 trials

Sponsors

Novartis Pharmaceuticals

Conditions

AsthmaChronic Obstructive Pulmonary Disease

Phase 3

Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01613326

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease

Start: 2012-06-30End: 2013-01-31Updated: 2014-04-23

Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS

WithdrawnNCT01757015

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease

Start: 2013-04-30End: 2014-04-30Updated: 2017-04-20

Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma

WithdrawnNCT02127697

Novartis PharmaceuticalsAsthma

Start: 2015-03-31End: 2017-05-31Updated: 2015-04-13

Phase 4

Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01922271

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease

Start: 2013-08-31End: 2014-01-31Updated: 2015-01-01

Related Papers

Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial.

2016-12-094 citations